| Programme | Time (SGT) |
|---|---|
| Welcome Remarks by the Conference Chairman and SHC partners | |
| Chronic Hepatitis B symposium Chairs: Prof. Junqi NIU, Prof. Harry Janssen, Prof. Rino Gani |
|
| Advances in HBV Cure 2024 – Prof. Man Fung Yuen, Hong Kong View Bio |
|
| New guidelines for CHB – Prof. Jidong Jia, China View Bio |
|
| Debate: Should treatment be expanded Yes: Prof. Man Fung Yuen, Hong Kong View Bio No: Prof. Heiner Wedemeyer, Germany View Bio |
|
| Stopping nucleoside analogue therapy: worth the risk? – Prof. Harry Janssen, Netherlands View Bio |
|
| Update on management of HBV flares – Prof. Teerha Piratvisuth, Thailand View Bio |
|
| Round table discussion/Case discussion | |
| GSK Meet the Experts Tea Break The building blocks of functional cure in HBV: Understanding the mechanisms and clinical considerations |
|
| Welcome and introduction – Prof. Lai Wei View Bio |
|
| The cornerstone: Defining the mechanisms needed to target functional cure – Dr. Kosh Agarwal View Bio and Prof. Lai Wei View Bio |
|
| The keystone: Measuring, monitoring and managing – Dr. Kosh Agarwal View Bio and Prof. Lai Wei View Bio |
|
| The capstone: Making functional cure last – Dr. Kosh Agarwal View Bio and Prof. Lai Wei View Bio |
|
| Summary and close – Prof. Lai Wei View Bio |
|
| Delta Cure Symposium Chairs: Prof. Teerha Piratvisuth , Prof. Khin Maung Win |
|
| What is the prevalence of delta hepatitis and how do you diagnose it – Prof. Pei Jer Chen, Taiwan View Bio |
|
| What is delta cure and how to achieve it? – Prof. Pietro Lampertico, Italy View Bio |
|
| Treatment options for delta cirrhosis – Prof. Heiner Wedemeyer, Germany View Bio |
|
| Round table/case discussion | |
| First GSK Symposium (lunch) Functional cure in HBV: Going the distance |
|
| Warm up: Introduction and housekeeping – Prof. Tatsuya Kanto View Bio |
|
| The functional cure triathlon: HBsAg loss, HBV-DNA suppression, and immune restoration – Prof. Lai Wei View Bio |
|
| Personal goals: What could functional cure mean for people living with CHB? – Prof. Thomas Tu View Bio |
|
| On the starting line: Current strategies to achieve functional cure – Prof. Tatsuya Kanto View Bio |
|
| Taking the torch: Future strategies that could achieve functional cure – Dr. Kosh Agarwal View Bio |
|
| Q&A – All Faculty |
|
| MASLD Symposium Chairs: Prof. Yock Young Dan, Dr. Poh Seng Tan, Dr. Yin Mei Lee |
|
| NAFLD, MAFLD, MASLD – practical implications of a name change. – Dr. George Goh, Singapore View Bio |
|
| Community screening and care pathways in Fatty Liver Disease – Prof. Wah Kheong Chan, Malaysia View Bio |
|
| Selecting patients for pharmacological treatment – Prof. Sven Francque, Belgium View Bio |
|
| Debate: Vitamin E for NAFLD Yes: Prof. Arun Sanyal, USA View Bio No: Prof. Vincent Wong, Hong Kong View Bio |
|
| Pearls and pitfalls on how to use GLP1 agonists – Dr. Mark Muthiah, Singapore View Bio |
|
| Summary of the Second Singapore MASLD Symposium – Prof. Arun Sanyal, USA View Bio |
|
| Round table/case discussion | |
| Fireside Chat with Hepatology experts: career pearls for clinicians and researchers Moderator: Dr. Daniel Huang |
|
| Featuring Prof. Rajender Reddy, View Bio Dr. Anand V Kulkarni, India View Bio & Prof. Arun Sanyal, USA View Bio | |
| End of day 1 | |
SHC 2024 Scientific Programme
July, 2024
26
July, 2024
27
| Programme | Time (SGT) |
|---|---|
| HCC Symposium Chairs: Dr. Edhel Tripon, Dr. Wei Lyn Yang, Adj. A/Prof. Chee Cheng Ean |
|
| Hepatocellular surveillance: Barriers, gaps and new strategies – Dr. Ken Liu, Australia View Bio |
|
| Role of non-invasive tests in NASH and HCC risk – Dr. Daniel Huang, Singapore View Bio |
|
| Debate: Adjuvant therapy for HCC Cure Yes: Prof. Pierce Chow, Singapore View Bio No: Prof. Glenn Bonney, Singapore View Bio |
|
| Updates in systemic therapy for HCC: the way forward – Adj. A/Prof. Chee Cheng Ean, Singapore View Bio |
|
| Round-table /case discussion | |
| Tea Break | |
| Other Liver Diseases Chairs: Dr. How Cheng Low, Dr. Kieron Lim, Prof. Bettina Hanssen |
|
| The forgotten disease: Alcoholic liver disease & MetALD – Prof. Ajay Duseja, India View Bio |
|
| Difficult to treat autoimmune hepatitis – Prof. Atsushi Tanaka, Japan View Bio |
|
| Biliary cirrhosis and sclerosing cholangitis: Update – Prof. Atsushi Tanaka, Japan View Bio |
|
| When should we consider rare liver diseases and how to diagnose it? – Prof. Bettina Hanssen, Holland View Bio |
|
| Round table/case discussion | |
| Lunch | |
| Advanced Liver Disease Management for the practising gastroenterologist/hepatologist Chairs: Dr. Rinaldi Lesmana, Prof. Raj Reddy |
|
| Hepatorenal syndrome and point of care ultrasound. – Dr. Anand V Kulkarni, India View Bio |
|
| Acute on chronic liver failure – Prof. Ajay Duseja, India View Bio |
|
| Preventing progression and complications of cACLD. – Dr. Ken Liu, Australia View Bio |
|
| When to refer patients for liver transplantation – Dr. Ruveena Bhavani Rajaram, Malaysia View Bio |
|
| Futility in liver transplantation – Prof. Rajender Reddy, USA View Bio |
|
| Round table/cases discussion | |
| Closing comments from the Chairman | |
